Michael Puskarich
Overview
Explore the profile of Michael Puskarich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
2262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castro-Pearson S, Samorodnitsky S, Yang K, Lotfi-Emran S, Ingraham N, Bramante C, et al.
Sci Rep
. 2024 Jul;
14(1):16370.
PMID: 39014194
No abstract available.
2.
Castro-Pearson S, Samorodnitsky S, Yang K, Lotfi-Emran S, Ingraham N, Bramante C, et al.
Sci Rep
. 2023 Nov;
13(1):20315.
PMID: 37985892
Significant progress has been made in preventing severe COVID-19 disease through the development of vaccines. However, we still lack a validated baseline predictive biologic signature for the development of more...
3.
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, et al.
JAMA
. 2023 Apr;
329(14):1170-1182.
PMID: 37039791
Importance: Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an...
4.
Lawler P, Derde L, van de Veerdonk F, McVerry B, Huang D, Berry L, et al.
JAMA
. 2023 Apr;
329(14):1183-1196.
PMID: 37039790
Importance: Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective: To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)...
5.
Bramante C, Proper J, Boulware D, Karger A, Murray T, Rao V, et al.
Open Forum Infect Dis
. 2022 Apr;
9(5):ofac066.
PMID: 35392460
Background: Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between...
6.
Lupei M, Li D, Ingraham N, Baum K, Benson B, Puskarich M, et al.
PLoS One
. 2022 Jan;
17(1):e0262193.
PMID: 34986168
Objective: To prospectively evaluate a logistic regression-based machine learning (ML) prognostic algorithm implemented in real-time as a clinical decision support (CDS) system for symptomatic persons under investigation (PUI) for Coronavirus...
7.
Pettit K, Messman A, Scott N, Puskarich M, Wang H, Alanis N, et al.
Emerg Med J
. 2021 Dec;
39(6):420-426.
PMID: 34933917
Background: Physician empathy has been linked to increased patient satisfaction, improved patient outcomes and reduced provider burnout. Our objective was to test the effectiveness of an educational intervention to improve...
8.
Thomas S, Puskarich M, Pulia M, Meltzer A, Camargo C, Courtney D, et al.
J Clin Pharmacol
. 2021 Dec;
62(6):777-782.
PMID: 34921684
Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) drugs may modify risk associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore, we assessed whether baseline therapy with ACEIs...
9.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith C, French C, et al.
Crit Care Med
. 2021 Oct;
49(11):1974-1982.
PMID: 34643578
No abstract available.
10.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith C, French C, et al.
Crit Care Med
. 2021 Oct;
49(11):e1063-e1143.
PMID: 34605781
No abstract available.